Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients

被引：45

作者：

Zhou, Shi ^{[1
]}

Khanal, Samrat ^{[1
]}

Zhang, Haijun ^{[1
]}

机构：

[1] Southeast Univ, Med Sch, Zhongda Hosp, Dept Oncol, 87 Dingjiaqiao Rd, Nanjing 210009, Jiangsu, Peoples R China

来源：

THERAPEUTICS AND CLINICAL RISK MANAGEMENT | 2019年 / 15卷

关键词：

immune-related adverse events; immune checkpoint inhibitors; nivolumab; ipilimumab; lung cancer; melanoma; CTLA-4; IMMUNOTHERAPY; METAANALYSIS; BLOCKADE; RECEPTOR; TRIAL; PD-1;

D O I：

10.2147/TCRM.S193338

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Purpose: The aim of this study was to evaluate the risk of immune-related adverse events (irAEs) among cancer patients receiving nivolumab-plus-ipilimumab therapy and nivolumab monotherapy. Patients and methods: PubMed and Web of Science were searched for related studies from inception to June 2018. Eligible studies included randomized controlled trials comparing nivolumab-plus-ipilimumab with nivolumab alone in cancer patients reporting on all-grade (grade 1-4) and high-grade (grade 3/4) irAEs. Paired reviewers selected studies for inclusion and extracted data. The odds risk and 95% CI were calculated. Results: A total of 2,946 patients from four studies were included in the meta-analysis. The underlying malignancies included lung cancer (two trials) and melanoma (two trials). Compared with nivolumab monotherapy, the nivolumab-plus-ipilimumab therapy was associated with a significantly higher risk of all-and high-grade irAEs such as pruritus, rash, diarrhea, colitis, alanine aminotransferase elevation, and pneumonitis. Conclusion: The combination therapy of nivolumab and ipilimumab increased the incidence of irAEs in patients with advanced cancer.

引用

收藏

页码：211 / 221

页数：11

相关论文

共 38 条

[1] Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports [J].

Abdel-Wahab, Noha ;

Shah, Mohsin ;

Suarez-Almazor, Maria E. .

PLOS ONE, 2016, 11 (07)

[2] Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial [J].

Antonia, Scott J. ;

Lopez-Martin, Jose A. ;

Bendell, Johanna ;

Ott, Patrick A. ;

Taylor, Matthew ;

Eder, Joseph Paul ;

Jaeger, Dirk ;

Pietanza, M. Catherine ;

Le, Dung T. ;

de Braud, Filippo ;

Morse, Michael A. ;

Ascierto, Paolo A. ;

Horn, Leora ;

Amin, Asim ;

Pillai, Rathi N. ;

Evans, Jeffry ;

Chau, Ian ;

Bono, Petri ;

Atmaca, Akin ;

Sharma, Padmanee ;

Harbison, Christopher T. ;

Lin, Chen-Sheng ;

Christensen, Olaf ;

Calvo, Emiliano .

LANCET ONCOLOGY, 2016, 17 (07) :883-895

[3] The PD1:PD-L1/2 Pathway from Discovery to Clinical implementation [J].

Bardhan, Kankana ;

Anagnostou, Theodora ;

Boussiotis, Vassiliki A. .

FRONTIERS IN IMMUNOLOGY, 2016, 7

[4] Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC) [J].

Emens, Leisha A. ;

Braiteh, Fadi S. ;

Cassier, Philippe ;

Delord, Jean-Pierre ;

Eder, Joseph Paul ;

Fasso, Marcella ;

Xiao, Yuanyuan ;

Wang, Yan ;

Molinere, Luciana ;

Chen, Daniel S. ;

Krop, Ian .

CANCER RESEARCH, 2015, 75

[5] Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma [J].

Faghfuri, Elnaz ;

Faramarzi, Mohammad Ali ;

Nikfar, Shekoufeh ;

Abdollahi, Mohammad .

EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (09) :981-993

[6] The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management [J].

Girotra, Monica ;

Hansen, Aaron ;

Farooki, Azeez ;

Byun, David J. ;

Min, Le ;

Creelan, Ben C. ;

Callahan, Margaret K. ;

Atkins, Michael B. ;

Sharon, Elad ;

Antonia, Scott J. ;

West, Pamela ;

Gravell, Amy E. .

JNCI CANCER SPECTRUM, 2018, 2 (03)

[7] Single versus combination immunotherapy drug treatment in melanoma [J].

Grimaldi, Antonio Maria ;

Marincola, Francesco M. ;

Ascierto, Paolo Antonio .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (04) :433-441

[8] Primer on tumor immunology and cancer immunotherapy [J].

Harris, Timothy J. ;

Drake, Charles G. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2013, 1

[9] Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions [J].

Hassel, Jessica C. ;

Heinzerling, Lucie ;

Aberle, Jens ;

Baehr, Oliver ;

Eigentler, Thomas K. ;

Grimm, Marc-Oliver ;

Gruenwald, Victor ;

Leipe, Jan ;

Reinmuth, Niels ;

Tietze, Julia K. ;

Trojan, Joerg ;

Zimmer, Lisa ;

Gutzmer, Ralf .

CANCER TREATMENT REVIEWS, 2017, 57 :36-49

[10] Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden [J].

Hellmann, M. D. ;

Ciuleanu, T. -E. ;

Pluzanski, A. ;

Lee, J. S. ;

Otterson, G. A. ;

Audigier-Valette, C. ;

Minenza, E. ;

Linardou, H. ;

Burgers, S. ;

Salman, P. ;

Borghaei, H. ;

Ramalingam, S. S. ;

Brahmer, J. ;

Reck, M. ;

O'Byrne, K. J. ;

Geese, W. J. ;

Green, G. ;

Chang, H. ;

Szustakowski, J. ;

Bhagavatheeswaran, P. ;

Healey, D. ;

Fu, Y. ;

Nathan, F. ;

Paz-Ares, L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2093-2104

← 1 2 3 4 →